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Sexually transmitted infections (STIs) are a variety of clinical infectious conditions caused by pathogens
that are transmitted through sexual activity. In recent years, the incidence of STIs has been gradually
rising, according to the statistics of the World Health Organization. Although the recommended man-
agement of people who have, or are at risk, for STIs were provided by the association of Europe and the
United States, the pathogens of STIs still have a great diversity of epidemiology in different ethnic
communities and countries. However, to our knowledge, there have been very few studies updating the
status of STIs in the Taiwan population. In this article, we focus on evaluations and announcements for
common pathogens of STIs in Taiwan. The strategies for prevention and control of STIs are also discussed
in this article. We hope that our experience can be shared to the neighboring countries and lead to an
Asian consensus of STI.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sexually transmitted diseases (STDs) are a variety of infectious
conditions that are caused by pathogens transmitted through sex-
ual activity. Recently, STDs have been renamed as sexually trans-
mitted infections (STIs) to avoid stigmatization. Based on the
statistics of the World Health Organization (WHO), the global
incidence of STIs has risen more than 10% from 2005 to 2008.1
About 499 million new cases of curable STIs (including gonor-
rhea, chlamydia, syphilis, and trichomoniasis) were reported in
2008, and the highest estimation was recorded in Asian countries,
including theWHOWestern Paciﬁc and Southeast Asia region, with
a total of more than 200million cases. The incidence of STIs has also
been gradually rising in Taiwan in the past decades. The increasing
trend may be attributed to numerous factors, including drug-
resistant pathogens, various coinfections, asymptomatic manifes-
tations, and sexually open societies. To make matters worse, mostohsiung Municipal TA-TUNG
strict, Kaohsiung City 80145,
-C. Tsai).
ociation. Published by Elsevier Tapatients tend to purchase over-the-counter drugs for self-
treatment. Inadequate dosage and inaccurate treatment usually
contribute to therapeutic failures and drug-resistant strains. Hence,
there is a pressing need for accurate strategies to control and pre-
vent STIs in Taiwan.
Sexual abstinence, appropriate precautions, and contraceptive
barriers are still the most reliable methods that prevent acquisi-
tion and transmission of STIs. Consistent and appropriate condom
use has been found to decrease human immunodeﬁciency virus
(HIV) and STI transmission by 64% and 42%, respectively.2 In the
early 2000s, the recommended management for STIs was sug-
gested in a synoptic overview by the European Association of
Urology.3 The guidelines for the treatment of people who have, or
are at risk, for STIs were also updated by the Centers for Disease
Control and Prevention in 2007, 2010, and 2015.4 However, these
guidelines seemed unsuitable for STIs in Taiwan. Because of
Eastern racial preferences and geographical relations, the cross-
border prostitution of Taiwanese mostly occurs within Asian
countries and the pathogens of STIs in Taiwan are different from
Western countries. Recent studies have also shown different
antimicrobial susceptibility results of urethral Neisseria gonor-
rhoeae and Chlamydia trachomatis strains between Asian and
Western countries.5,6 Therefore, it is important to develop an
Asian consensus of STIs.iwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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established in 2010.7 Accumulated expertise supplemented with
clinical pictures of Taiwanese were also collected and issued in
the “Atlas and Treatment Guidelines of Sexually Transmitted
Diseases” in 2015.8 Moreover, there are two major strategies for
the prevention and transmission of STIs in Taiwan. First, physi-
cians must report diagnosed cases of syphilis, gonorrhea, and HIV
to public health authorities. The patients with diagnosed syphilis
and gonorrhea should be notiﬁed within 1 week and those with
HIV should be notiﬁed within 24 hours. Taiwan Health Ministry
and Centers for Disease Control (Taiwan CDC) can collect data
and provide the current information regarding these threatening
STIs. Second, to further improve the quality of STIs care services
and encourage patients to seek reliable treatment, Taiwan CDC
has asked relevant societies and associations to assist the
training of the STD-friendly physicians since 2010. As of the end
of 2013, a total of 1160 STD-friendly physicians were recom-
mended and have made great contribution to STIs management
in Taiwan.8
2. STIs and HIV screen
Worryingly, the data compiled by Taiwan CDC reveals that the
number of HIV-positive patients increased from 20,801 in
January 2011 to 32,045 in December 2015, reﬂecting a signiﬁcant
increase over the past 5 years. HIV infection is concentrated in
speciﬁc populations, including drug abusers, sex workers and
STI-infected individuals. In the past decades, HIV transmission in
Taiwan has risen due to the sharing of needles between drug
abusers. After conducting the programs of “Not Sharing Needles
and Syringes” by Taiwan CDC, the number of HIV infections by
injection has now decreased to less than 100 people per year.
The major mode of HIV transmission in Taiwan has become
through unprotected sexual behaviors. Among 2384 new HIV-
positive patients in 2015, more than 88% of infections were
contracted through sexual behaviors. Among these HIV-positive
patients, more than 97% were men and 75% of them were men
who have sex with men (MSM). MSM are at an independent risk
for HIV acquisition, particularly those who have multiple sex
partners and abuse recreational drugs.9 Recreational drugs,
which could enhance sensory stimulation, sexual performance,
and orgasm, are very popular amongst MSM. However, using
condoms becomes very uncomfortable owing to drug-related
hyper sensitivity. Most recreational drugs, especially metham-
phetamines, usually cause inconsistent condom use among MSM
and lead to STIs and HIV transmission. Because STIs are impor-
tant cofactors in HIV transmission, health providers should
remind STI-infected individuals to beware of the risks of con-
tracting HIV.10 Since 2008, Taiwan CDC suggested that all pa-
tients with STIs should undergo HIV screening. The outcome
showed that ~0.5% of such patients are coinfected with HIV,
especially patients with syphilis and genital warts.8 Because HIV
infectors would decrease their exposure to unprotected sex by
68% after becoming aware of their own infection,11 Taiwan CDC
provides 405 free anonymous counseling and testing agencies
for suspected HIV infectors. Furthermore, because the window
period is 6e12 weeks, even after receiving a negative screening
test, all suspected infectors are reminded to take another test
3 months later and refrain from unprotected sexual behavior or
donating blood. Taiwan CDC also utilizes community engage-
ment to conduct the programs of “I-Check & We-Check HIV
Testing” and stipulate 27th June as the National HIV Testing Day.
Taiwan CDC also provides post-exposure prophylaxis and pre-
exposure prophylaxis for people, who are exposed or will have
unprotected sex with suspected HIV infectors, at their ownexpense. These strategies indeed have made great contribution
to HIV prevention and control in Taiwan.
3. Syphilis
The diffusion of syphilis is usually limited because 95% of cases
lose infectivity after 6 months and direct transmission is rare after
5 years of infection.12 Compared with 2005, there was no obvious
change in the incidence of syphilis, according to WHO statistics in
2008.1 In Taiwan, the incidence of syphilis is the highest in patients
aged over 70 years in recent years (Figure 1). Most of them have late
latent syphilis with relatively low seroreactivity and are detected by
elderly health examination. These patients with latent syphilis
might have been infected by military sex workers during “World
War II” or “Chinese Civil War” and received inaccurate diagnosis
and treatment at the time. Moreover, the transmission might be
more diffused by blood contamination due to incomplete sterili-
zation of medical instruments in rural areas. Since symptoms of
syphilis would be self-limited without accurate treatment, this
would result in most patients entering the latent stage without
awareness. Because only 33% patients with late latent syphilis
might progress to tertiary syphilis, close follow-up or prophylactic
treatment could be considered for these patients.12 However, it
should be remarked that the incidence of primary and secondary
syphilis has increased gradually in young adults aged 20e30 years
(Figure 1). This indicates that syphilis is transmitted amongst
sexually active populations in Taiwan. To enhance the consistency
of diagnosis rate and notiﬁcations, the “Upgrading Draft to Deﬁne
Notiﬁcations of Syphilis and Congenital Syphilis” was issued by the
Taiwan CDC in 2015, which removed the former common nouns,
such as active and inactive syphilis, and switched them to primary,
secondary, tertiary, and latent syphilis. Syphilis is diagnosed
according to the clinical presentation and one of the following
positive laboratory tests: (1) specimens can be tested for Trep-
onema pallidum by darkﬁeld microscopy, direct immunoﬂuo-
rescence, or nucleic acid detection; (2) for untreated or unknown
patients, positive results of nontreponemal tests and treponemal
tests are performed; (3) for patients who have been treated, the
titer of nontreponemal test is re-elevated four times or more;
and (4) positive results of cerebrospinal ﬂuid nontreponemal
test.
The updated management for different stages of syphilis is
shown in Table 1. All sexual partners should accept inspection.
Patients should avoid sexual activity for 14 days after complete
therapeutic regimen and symptomatic remission. The quantitative
nontreponemal test should be repeated at 6 months, 12 months,
and 24 months after treatment.
4. Gonorrhea
Due to the increase in drug-resistant strains and sexually open
societies, the incidence of N. gonorrhoeae drastically increased in
recent years. From 2005 to 2008, the incidence of N. gonorrhoeae
in patients aged 15e49 years increased by 21%.1 In Taiwan, the
incidence is also on the rise and the reported number of new cases
increased from 2011 in 2011 to 3585 in 2015 (Figure 2). It is
believed that the incidence of gonococcus urethritis (GU) is likely
much higher than reported due to the over-the-counter drugs,
low sensitivity of testing methods, unconﬁrmed treatments, and
troublesome notiﬁcation systems. Gonorrhea is diagnosed ac-
cording to the clinical ﬁndings and laboratory tests, including
microscopy, cultures, or nucleic acid ampliﬁcation tests (NAATs).
The sensitivity and speciﬁcity of NAAT is usually superior to that of
other tests. To establish the antimicrobial susceptibility of the
strain, the culture test is strongly suggested for all suspected
Figure 1. The incidence of syphilis in all ages in Taiwan, from 2010 to 2014.
Table 1
Management for different stages of syphilis.a,b,c
Titer of serological
tests
Remarks Recommended regimen
Primary or secondary syphilis (1) VDRL/RPR 1:8
(2) Positive TPHA
Symptomatic manifestation in clinics Benzathine penicillin G 2.4 million units IM in a single dose
Early latent syphilis (1) VDRL/RPR 1:4
(2) Positive TPHA
(1) No clinical symptoms
(2) Be infected within 1 y
Late latent syphilis (1) Sometimes
VDRL/RPR < 1:4
(2) Positive TPHA
(1) No clinical symptoms
(2) Be infected >1 y
Benzathine penicillin G 2.4 million units IM once/wk for 3 wks
Successful treatment (1) VDRL/RPR titer
decrease > 4 times
or turn to negative
(2) TPHA usually
positive
(1) After complete therapeutic regimen, the nontreponemal test might show low positive titer or negative
seroreactivity
(2) In 1 y after complete therapeutic regimen, the negative seroreactivity rate of nontreponemal test in
primary & secondary syphilis are 40e75% & 20e40%, respectively
(3) 15e25% of patients treated during the primary syphilis could revert to negative seroreactivity of
treponemal test after 2e3 y
False positive (1) VDRL/RPR
showed low
positive
seroreactivity
(2) Negative TPHA
False positive may be caused by aging or autoimmune diseases such as systemic lupus erythematosus
Reinfection or relapse VDRL/RPR rebound
& increase for > 4
times with/without
clinical symptoms
Additional treatment with recommended regimen
RPR ¼ Rapid Plasma Reagin; TPHA ¼ T. pallidum hemagglutination assay; VDRL ¼ Venereal Disease Research Laboratory.
a The alternative regimens of patients with penicillin allergy are as follows: (1) primary, secondary, and early latent syphilis: doxycycline 100 mg orally twice a day for
14 days or tetracycline 500mg orally four times a day for 14 days; however, pregnant woman are not allowed to use; (2) late latent of syphilis: doxycycline 100mg orally twice
a day for 28 days or tetracycline 500 mg four times a day for 28 days; however, pregnant woman are not allowed to use.
b The medication as below are not efﬁcient in some area and are listed as second treatment for primary, secondary, and early latent syphilis: (1) azithromycin 2 g orally in a
single dose; (2) ceftriaxone 1e2 g IV push once a day for 10e21 days.
c If nontreponemal test shows a positive reaction it represents that the patient has current or previous Treponema pallidum infection.When TPHA shows positive reaction (
1:320) it represents that the false positive seroreactivity of nontreponemal test may not cause by syphilis when TPHA shows negative reaction (< 1:80). If it is still doubtful and
should be retested or followed up when TPHA titer ¼ 1:80 or 1:160.
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decades include sulfonamides in 1930s, penicillin in 1940s,
tetracycline in 1960s, and quinolones in 1990s. However, most of
these antimicrobials are no longer recommended according to the
epidemiology of antimicrobial susceptibility results, especially in
Asia.6 In response to the emerging antimicrobial resistance and
threatening untreatable gonorrhea, there are several recommen-
dations as follows. (1) The update management for gonorrhea is
shown in Table 2. A dual therapy with ceftriaxone (500 mge1 g
IM/IV) plus azithromycin (1 g) orally in a single dose is the rec-
ommended regimen. Not only covering the common coinfection
of C. trachomatis, the dual therapy can also increase treatmentefﬁcacy and decrease cephalosporin-resistant strains.4,13,14 Inci-
dentally, more and more gonococcal strains with high-level
ceﬁxime and ceftriaxone minimum inhibitory concentrations
have been reported; therefore, the Asian guidelines suggest a
higher initial dose of ceftriaxone with from 500 mg to 1 g IM/IV
and no longer recommend ceﬁxime as a ﬁrst-line drug of
choice.15,16 (2) The incidence of rectal and pharyngeal infection
has gradually increased in recent years, and the cephalosporin-
resistant strains have increased in these atypical infections.16,17
Clinicians should perform culturing and consider the highest
dose with ceftriaxone 1 g IM/IV. (3) Patients with gonorrhea
should refrain from sexual behavior for at least 7 days after the
Figure 2. The annually cumulative cases of gonorrhea in Taiwan, from 2011 to 2015.
Table 2
Recommended management for gonorrhea infection.a,b
Recommended regimen Remarks
Urethritis;
Proctitis;
Cervicitis
Ceftriaxone from 500 mg to 1 g IM or IV in a single dose (1) The 1st choice of treatment
(2) Because of increasing resistance trend in Asian population, primary
treatment with a relatively high dose is strongly recommended
Ceﬁxime 400 mg orally in a single dose (1) It is used when ceftriaxone is not available
(2) All patients need to repeat test of gonorrhea 1 wk after treatment
Azithromycin 2 g orally or spectinomycin 2 g IM in a single dose (1) Only when patients are severely allergic to cephalosporin
(2) All patients need to repeat test of gonorrhea 1 wk after treatment
Pharyngitis Ceftriaxone 1 g IM or IV in a single dose Because of an increasing resistance trend in the Asian population, primary
treatment with a relatively high dose is strongly recommended
Conjunctivitis Ceftriaxone 1 g IM or IV in a single dose It is for adults
Ceftriaxone 25e50 mg/kg IV or IM in a single dose (1) It is for neonates, & the total dose cannot exceed 125 mg
(2) Antibiotic ointment is not enough for treatment & only used for
prevention
Meningitis Ceftriaxone 1e2 g IV every 12 h Drug administration for 10e14 d
Endocarditis Ceftriaxone 1e2g IV every 12 h Drug administration for > 4 wks
a Cephalosporin can be used with IV slow push and the efﬁcacy is similar with IM injection. Because of increasing resistance trend, penicillin, quinolone, and tetracycline are
not recommended for the treatment of gonorrhea now.
b Because the cephalosporin resistance of gonococcal urethritis increases rapidly and gonorrhea is often accompanied with chlamydial urethritis, additional medicine with
azithomycin 1 g orally in a single dose is suggested to give with recommended regimens at the same time. The dual therapy for gonococcal infection can not only increase the
efﬁciency of treatment, but also cure potential chlamydial urethritis. The dose of azithomycin could increase to 2 g according to clinical conditions and patient's weight. If
patients are severely allergic to azithromycin, oral medication of doxycycline 100 mg orally twice a day for 7 days could be considered.
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suggests that persons who have sexual contact with infectors
within the preceding 10 days should be screened and considered
to have presumptive treatment. All patients should receive testing
for common co-STIs, including chlamydia, HIV, and syphilis.
5. Nongonococcal urethritis
Nongonococcal urethritis (NGU) is caused by various infectious
pathogens, including C. trachomatis, Trichomonas vaginalis, Myco-
plasmas, and herpes simplex virus (HSV).18e20 Because of its similar
and minimally symptomatic manifestation, NGU is still a concern-
ing disease for physicians in clinics. The common diagnostic
method to detect pathogens is using a urethral swab to collectspecimens for cultures or microscopy, hybridization tests, enzyme
immunoassay (EIA), or NAATs.20 With the multiple targeting abil-
ities, many STIs pathogens can be detected by NAAT in one sample.
Therefore, NAAT has now been gradually accepted and considered
as the ﬁrst-line diagnostic tool.
C. trachomatis is the most common pathogen in patients with
NGU and accounts for approximately 15e40% of cases of initial
NGU.19 Not only NGU, C. trachomatis has also been recognized as a
cause of pelvic inﬂammatory disease and epididymitis, even some
chronic prostatitis.4,21 In men younger than 35 years, the most
common pathogens of acute epididymitis are C. trachomatis and
N. gonorrhoeae. By contrast, C. trachomatis serovars L1, L2, and L3
could cause uncommon lymphogranuloma venereum, which usu-
ally presents with unilateral tender inguinal and/or femoral
C.-C. Tsai et al. / Urological Science 27 (2016) 122e130126lymphadenopathy.22 Besides NAATs, a rapid antigen-detection test
could be considered as an alternative diagnostic method of chla-
mydia infection. However, the test has a very low sensitivity.
Because NGU induces a weak immunological response and anti-
body cannot distinguish between previous and current infections,
systemic serological tests are not useful in diagnosis of chlamydial
urethritis.23 The serology test might be used to screen chlamydia-
related pneumonia, epididymitis, and lymphogranuloma vene-
reum. To prevent further transmission, a presumptive treatment
should be considered at the time of NGU diagnosis.4 In clinical
practice, azithromycin is superior to other recommended regimens
because of its high compliance with single dose and less gastroin-
testinal tract upset. Sexual behavior should be prohibited during
the therapeutic period. For GU, Taiwan CDC suggests a concomitant
survey and, if necessary, treatment for all sexual partners of the
infected person within the preceding 10 days. In clinics, recurrent
or persistent NGU was usually caused by inadequate regimen,
incomplete treatment, or reinfection. However, if both the recom-
mended antibiotics of chlamydia infection are not useful in cases of
chronic NGU, other pathogens should be considered. Mycoplasmas,
T. vaginalis, and HSV have been identiﬁed as the dominant causes of
nonchlamydial NGU (NCNGU).19,20
Mycoplasmas represent several original species. Among them,
M. genitalium is thought to be the most prevalent pathogen in
humans and causes approximately 15e20% of NGU, 20e25% of
NCNGU, and 30% of persistent or recurrent urethritis.24 NAAT is the
only useful method for the diagnosis of M. genitalium-related NGU
because the traditional culture is very difﬁcult, time consuming,
and less sensitive.4,25 The recommended antibiotics are the same as
those for chlamydial urethritis because both the respective causa-
tive pathogens have no cell wall. However, the 7-day tetracycline or
doxycycline regimen is not recommended for the ﬁrst-line regimen
due to relatively lower cure rate recently. A single 1-g dose of azi-
thromycin seems more effective.26
T. vaginalis-related trichomoniasis is the most prevalent
nonviral STI and 276.4 million new cases acquired it in 2008.1
Approximately 1e20% cases of NGU are thought to be caused by
T. vaginalis. In fact, 75% of infected men are symptomatic. Other
infected male patients may exhibit symptomatic NCNGU, balano-
posthitis, epididymitis, urethral stricture, prostatitis, infertility, and
even prostate cancer.27,28 Besides traditional microscopic exam and
culture, trichomoniasis has been detected using NAATs by testing
urogenital secretions or ﬁrst-void urine in recent times. The FoodTable 3
Recommended management for nongonococcal urethritis (NGU).a,b,c
Recommended regimen
Chlamydial urethritis Azithromycin 1 g orally in a single dose or doxy
minocycline 100 mg orally twice/d for 7 d
Lymphogranuloma venereum Doxycycline 100 mg orally twice/d for 21 d or er
500 mg every 6 h for 21 d or azithromycin 1 g o
3 wks
Acute epididymitis caused by
sexually transmitted
infections
Ceftriaxone 500 mge1g IM or IV in a single dos
doxycycline 100 mg orally twice/d for 10 d
Ceftriaxone 500 mge1g IM or IV in a single dos
levoﬂoxacin 500 mg once/d for 10 d
Mycoplasma-related urethritis Azithromycin 1 g orally in a single dose
Trichomonas vaginalis-related
urethritis
Metronidazole 2 g or tinidazole 2 g orally in a s
a The antimicrobials below have been listed as second treatment of chlamydial uret
levoﬂoxacin 500 mg once a day for 7 days; (2) oﬂoxacin 300 mg twice a day for 10 days
b The antimicrobials below could be considered for drug-resistance strain ofMycoplasm
once a day for 4 days; (2) moxiﬂoxacin 400 mg once a day for 7e14 days; and (3) sitaﬂo
c Metronidazole 500 mg twice a day for 7 days could be considered as the alternativeand Drug Administration (FDA)-approved rapid antigen test, which
is available at the point of care, has become more popular in recent
clinical practice, but it needs more study in men.4,29 The recom-
mended regimen is a single 2-g dose of metronidazole or tinida-
zole. To prevent a disulﬁram-like reaction, patients should avoid
consuming alcohol during the therapeutic period within at least
24 hours after completion of metronidazole or 72 hours after
completion of tinidazole.30 The prevalence of T. vaginalis infection is
even as high as 73% in male sexual partners of women who had
trichomoniasis.31 Therefore, if the sexual partner has been diag-
nosed with trichomoniasis, a man with NGU should be screened
and treated, if necessary, for T. vaginalis infection.
HSV has also been recognized as a pathogen of NCNGU. HSV,
usually type 1, also causes 2e5% cases of NGU.18 Classical symptoms
of NGU are noted in approximately one-third of menwith a primary
HSV infection.20 Patients with chronic NCNGU may be tested for
HSV infection if the patient or sexual partners have genital herpes
history. Finally, clinical strategies and algorithms for NGU in men in
Taiwan are described in Table 3 and Figure 3, respectively.
6. HSV
Genital herpes can be caused by both HSV-1 and HSV-2.
Symptoms of the primary episode usually occur within 2 days to
2 weeks after exposure to the virus and last weeks.32 After that, the
virus lurks in the ganglion, relapses when immunity is decreased,
and causes chronic, life-long viral infection. Compared with severe
primary infection, recurrent episode is less serious and often has a
prodrome. HSV-1 causes ~50% of primary genital herpes and cause
more severe symptoms; however, its recurrence is much less
frequent than that of HSV-2 infections. Recently, with a high fre-
quency of oral and anal sex, an increasing proportion of anogenital
HSV-1 infection has been noted.33 By contrast, primary HSV-2
infection mostly causes minimal or no symptoms, but it is easy to
relapse.32,34 Most recurrent genital ulcers are caused by HSV-2
infection.
The diagnosis of HSV infection is based on the clinical mani-
festation and virological tests. NAAT or cell culture tests, which
allow simultaneous virus detection and typing, are more reliable.
HSV antigen detection by EIA and direct immunoﬂuorescence as-
says are also available, but these methods have lower sensitivity
and no virus typing.35 The traditional serological tests can detect
type-speciﬁc or -common antibodies to HSV. Type-speciﬁc assaysRemarks
cycline/ Higher dose with azithromycin 2 g can be considered for a drug-
resistance strain
ythromycin
nce/wk for
The diagnosis might be supported by chlamydia serology test. If
local abscess has formed, needle aspiration or surgical drainage
is recommended
e plus Acute epididymitis in patients younger than 35 y is usually
caused by Chlamydia trachomatis & Neisseria gonorrhoeae
e plus Patients who have anal sex
This pathogen should be considered for patients with chronic
NGU or sexual partners have history of Mycoplasma infection
ingle dose This pathogen should be considered if patients present with
chronic NGU & sexual partners have symptoms or history of
trichomoniasis. Combination usage of drugs & alcohol would
produce the threatening disulﬁram-like reaction
hritis now according to the trends in resistance of urethral Chlamydia strains: (1)
; and (3) erythromycin 500 mg every 6 hours for 7 days.
a urethritis: (1) azithromycin 500 mg orally once, followed by azithromycin 250 mg
xacin 100 mg twice a day for 7 days.
regimen for trichomonas urethritis if the single-dose regimen fails.
Figure 3. The algorithm for the management of non-gonococcal urethritis in male.
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protein G2 (HSV-2) and are superior to type-common assay in
clinical settings. However, the serological test is not recommended
as a routine diagnostic or screening tool because it cannot distin-
guish past infection from current infection.4,34 For patients with
latent-virus infection, the serological test does not distinguish
anogenital infection from orolabial infection. Many asymptomatic
persons who are HSV-1 seropositive suffer from psychosocial
stress.33,36 Immunoglobulin G (IgG) testing, which usually becomes
detectable 2e12 weeks after primary infection, might be useful in
the following settings: (1) recurrent or atypical vesicles/ulcers in
genital area with negative NAAT and/or culture; (2) ﬁrst-episode
genital herpes to distinguish primary (PCRþ; IgG) infection
from recurrent (PCRþ; IgGþ) infection; and (3) clinical diagnosis of
genital herpes without previous laboratory conﬁrmation.
Conversely, the immunoglobulin M serological test has limited
availability in clinic because it is not type-speciﬁc and might be
negative during primary herpes infection and long-term persis-
tence in chronic herpes.4
All primary genital herpes should be treated with systemic
antiviral regimens to prevent severe or prolonged genital symp-
toms and neurological involvement, offering clinical beneﬁts to
most symptomatic patients. For recurrent genital herpes, which is
usually self-limited, episodic treatment needs to be used during the
prodrome or within 1 day of lesion onset. Effective episodic treat-
ment can control the symptoms and decrease the duration of
herpes episodes; however, it cannot destroy latent viruses or
decrease the risk, frequency, or severity of recurrences in the
future.34 Suppressive antiviral therapy should be used for patients
with recurrent HSV outbreaks for more than six times per year. Not
only can it decrease the frequency of genital herpes recurrences by
70e80%, but has also been reported as a strategy to prevent
transmission.4 Topical therapies with antiviral drugs have only
limited beneﬁts. For oral herpes, acyclovir 5% cream shortens the
duration of episode by 0.5e0.6 days and duration of pain by
0.3e0.4 days after a 4-day course of therapy.37 In other respects,
lifestyle modiﬁcation with adequate rest, nutrition, exercise, and
stress management are effective to control the outbreaks of herpes.
The recommended management for genital HSV infection is shown
in Table 4. Patients who have clinical HSV outbreaks should refrain
from sexual behavior; however, transmission can occur with sub-
clinical viral shedding.34,35Table 4
Recommended management for genital herpes simplex virus (HSV).a,b,c
Recommended regimen
Primary infection (1) Acyclovir 400 mg orally 3 times/d for 7e10 d
(2) Acyclovir 200 mg orally 5 times/d for 7e10 d
(3) Famciclovir 250 mg orally 3 times/d for 7e10 d
(4) Valacyclovir 1g orally twice/d for 7e10 d
Recurrent episode (1) Acyclovir 200 mg orally 5 times/d for 5 d
(2) Acyclovir 400 mg orally 3 times/d for 5 d
(3) Acyclovir 800 mg orally 3 times/d for 2 d
(4) Famciclovir 125 mg orally twice/d for 5 d
(5) Famciclovir 1 g orally twice/d for 1 d
(6) Famciclovir 500 mg orally once, followed by famcic
250 mg orally twice/d for 2 d
(7) Valacyclovir 500 mg orally twice/d for 3e5 d
(8) Valacyclovir 1 g orally once/d for 5 d
Suppressive therapy (1) Acyclovir 200 mg or 400 mg orally twice/d
(2) Valacyclovir 500 mg or 1 g orally once/d
(3) Famciclovir 250 mg orally twice/d
a Suppressive antiviral therapy could decrease the recurrent rate and the risks of transm
after treatment; however, the medication should be stopped and re-evaluated for the n
b Valacyclovir 500 mg orally is not recommended when HSV recurrence occurs > 10 t
c If patients' weight is < 60 kg, acyclovir 200 mg orally twice a day is enough to proce7. Human papillomavirus
More than 40 types of human papillomavirus (HPV) have been
recognized as pathogens in humans. The low-risk types (e.g., HPV
types 6 and 11) cause 90% of anogenital warts. Other high-risk types
(e.g., HPV types 16, 18, 31, 33, 45, 52, and 58) are highly correlated
with several types of carcinogenesis.38 Because the virus would lose
activity and infectivity in a short episode after being shipped out of
the cell, HPV infection is typically acquired during sexual contact. In
fact, most sexually active persons have acquired HPV infections in
their lifetime and could clear it spontaneously by the immune
system.39 However, the virus still may remain latent for months to
years until a trigger causes replication of viral DNA. The latency
usually depends on the immunity of infectors and the activity of
HPV. It is worth noticing that HPV could be transmitted in the in-
cubation or latent period.40 Anogenital warts could be diagnosed by
clinical appearance. Biopsy is indicated if lesions are ulcerated,
pigmented, bleeding, afﬁxed, or nonresponsive to standard ther-
apy.4 The updatemanagement is shown in Table 5. There is not yet a
reliable method that can be used to detect whether patients are in
their incubation period or HPV is eradicated after treatment or not.
Dry skin or mucosa brushing for HPV virological tests has high
speciﬁcity but relatively low sensitivity, and is usually used in oral
cavity and oropharynx.41
There are two HPV vaccines approved in Taiwan. The quadri-
valent vaccine has efﬁcacy against lesions related to HPV types 6,
11, 16, and 18, and the bivalent vaccine can prevent HPV types 16
and 18 infection. HPV vaccines should be applied in a 3-dose
series over a 6-month period, but not in pregnant women.
Because recent studies showed sufﬁcient immunogenetical value,
WHO approved that the bivalent vaccine could be administered as
a 2-dose series with the second doses given 1 month, 2 months,
or 6 months after the ﬁrst dose in 9e14-year-old girls.42 The ef-
ﬁcacy of HPV vaccine against external genital and anal lesions is
90.4% and 77.5%, respectively, for 5 years. The most common side
effect is muscle pain at the injection site, but it is usually self-
limited.43e45 It should be comprehended that, in the Asian pop-
ulation, HPV types 16 and 18 only account for 66% of all cervical
cancers.46 Therefore, people who have received HPV vaccine
should continue to prevent HPV infectionwith consistent condom
use and screen cervical cancer with pap smears. By contrast, the
9-valent vaccine approved by the FDA, which prevents infectionRemarks
(1) Positive virological tests; HSV-IgG-negative mostly
(2) Antiviral regimen is recommended to be used for reducing
severe or prolonged clinical symptoms & neurologic
involvement
lovir
(1) Positive virological tests; HSV-IgG-positive
(2) Most recurrent outbreaks are self-limited & only need
supportive treatment. Antiviral regimen needs to be used
during the prodrome or within 1 d of lesion onset. It also cannot
reduce the risk, frequency, or severity of recurrences
It is recommended to be used when recurrence occurs > 6
times/y
ission to sexual partners. It would have clinical efﬁcacy within the ﬁrst 3e6months
ecessary of continuous usage after 1 year.
imes/y because of its lower efﬁcacy.
ed with suppressive antiviral therapy.
Table 5
Recommended management for anogenital warts.a
Method Recommended regimen Remarks
Patient-applied
topical agents
(1) Podophyllotoxin 0.5% solution or gel (Wartec): It is recommended
for wart area  10 cm2 & each dose should not exceed 0.5 mL. It should
be applied twice/d for 3 d & followed by 4 d of rest. The therapeutic
cycle could be repeated for up to 4 cycles.
Clearance rate: 45e77%
Recurrence rate: 38e65%
(2) Imiquimod 3.75% or 5% cream: It should be applied once/d, 3 times/
wk. This agent is recommended for bedtime application& should not be
continued for > 16 wks
Clearance rate: 56e84.5%
Recurrence rate: 13e16%
(3) Sinecatechins 10% or 15% ointment: It should be applied 3 times/d.
This agent should not be continued for > 16 wks
Clearance rate: 40e58%
Recurrence rate: 6e10%
(4) 5-Fluorouracil 5% cream: it should be applied once/d or twice/d Clearance rate: 10e50%
Recurrence rate: 50%
Provider administered
treatment
(1) Surgical excision for large pedunculated or atypical lesions Clearance rate: 72%
Recurrence rate: 19e29%
(2) Cryotherapy: it should be applied once/wk up to 12 wks Clearance rate: 79e88%
Recurrence rate: 25e40%
(3) Laser ablation or electrocautery diathermy Clearance rate: 23e52%
Recurrence rate: 60e77%
(4) Chemical agents with 80e90% solution of trichloroacetic acid &
dichloroacetic acid: It should be applied 1e3 times/wk & repeated as
necessary
Clearance rate: 64e88%
Recurrence rate: 36%
(5) Photodynamic therapy Clearance rate: 85.7e95.3%
Recurrence rate: 9.38e14.3%
(6) Intralesional antigen immunotherapy Clearance rate: 66.7%
Recurrence rate: nil after 3 mo
(7) Podophyllin 20e25% solution: it is recommended for wart area 
10 cm2 & each dose should not exceed 0.5 mL. It should be washed off
after 1e4 h & applied once/wk for up to 8 wks
Clearance rate: 42e46.9%
Recurrence rate: 46e60%
(8) Interferon: it should be locally used (intralesional injections or
topical applications)
Clearance rate: 17e67%
Recurrence rate: 9e69%
a Treatment should be modiﬁed by lesion size, number, anatomic site, and patient preference. Because giant warts are easily occurred in pregnant women, surgical excision
or cryotherapy should proceed as soon as possible for pregnant women with anogenital warts. Patient-applied topical agents cannot be applied for pregnant women.
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suitable for Asian and Taiwanese populations in recent clinical
practice.40
In clinical practice, HPV vaccines are only recommended for
uninfected populations aged 9e26 years.45 However, because of
conservative customs and traditions, there are still many adults
without sexual experience in Taiwan. Furthermore, even if they
have been subclinically infected by a particular HPV type, the
HPV vaccine can yet provide protection to cover other HPV
types. Therefore, although it is off-label used, we suggest that
people older than 26 years without HPV-infected history still
can have HPV vaccination, regardless of their sexual experi-
ences. To prevent HPV transmission, since 2010, more and more
Taiwan local governments have put into practice policies that
13e18-year-old-girls can receive free education, intervention,
and HPV vaccination. Other Asian countries also have imple-
mented nation-wide programs providing HPV vaccines to
adolescents.47e49 However, in recent years, few severe adverse
events led to HPV vaccination crisis in Japan.50 Hence, further
large-scale prospective studies, including epidemiological and
pathological exploration, are necessary to elucidate the safety,
cost-effectiveness, and equity impacts of these school-based
HPV vaccination programs.8. Conclusion
With the opening up of sexual societies with time, STIs have
become a serious health issue in Taiwan. Cross-border prostitution
behaviors have also caused the spread of STIs pathogens between
Taiwan and regional countries. In this article, we reviewed the
updated strategies for prevention and control of STIs in Taiwan. Our
experience can be hopefully shared with the neighboring countries
and lead to an Asian consensus of STI.Conﬂicts of interest
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